Clinical trials
Full profile accessFollow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
ET019002-T
- Development stage
- Phase 1
- Lead developer
- Eureka Therapeutics
- Modality
- CAR-T Cells → Engineered T Cells → Adoptive Cell Transfer → Cell Therapies
- Administration
- Intravenous
01
Overview
ET019002-T is an **autologous T cell therapy** genetically engineered to express a novel anti-CD19 chimeric antigen receptor (CAR) for the treatment of **relapsed/refractory B-cell malignancies**. Developed using the ARTEMIS platform by Eureka Therapeutics, these T cells are transduced via lentivirus with an anti-CD19 single-chain variable fragment (scFv) fused to CD28, granting targeted antitumor effects against CD19+ cells. ET019002-T demonstrates similar efficacy to classical CAR-T cells in preclinical studies with significantly lower inflammatory cytokine release, aimed at improving safety in clinical use. Clinical administration is performed via intravenous infusion, following pre-conditioning with cytotoxic agents when appropriate. Early clinical trials report safety and preliminary efficacy, including cases of complete remission in advanced disease[1][2][4][6][8][9][10].
- Other names
- ET019002ET-019002ET 019002ET019002-T cellsET-019002-T cellsET 019002-T cells
02
Targets
Beyond the preview
Go deeper on ET019002-T.
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Indications & development
Full profile accessExplore development by indication, patient population, and geography.
- Indications
- Development status
- Countries
Licensing & deals
Full profile accessTrace asset ownership, licensing agreements, and commercial partnerships.
- Partners
- Deal terms
- Milestones
Patents & exclusivity
Full profile accessExplore the patent landscape and regulatory exclusivity around an asset.
- Patents
- Expiration dates
- Exclusivity
Competitive landscape
Full profile accessCompare development programs by target, modality, and indication.
- Competing assets
- Targets
- Development stage
Research & analysis
Full profile accessConnect source evidence and development news to your research questions.
- Publications
- News
- Analysis
Bring the full picture into focus.
See how Gosset can support your research on ET019002-T.